50 results on '"D'Souza, Deborah N."'
Search Results
2. Florbetapir F18 PET Amyloid Neuroimaging and Characteristics in Patients With Mild and Moderate Alzheimer Dementia
3. A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment
4. Atomoxetine Treatment Outcomes in Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder: Results From a Post Hoc, Pooled Analysis
5. A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder
6. Characteristics of Placebo Responders in Pediatric Clinical Trials of Attention-Deficit/Hyperactivity Disorder
7. Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder
8. Tandospirone activates neuroendocrine and ERK (MAP kinase) signaling pathways specifically through 5-HT1A receptor mechanisms in vivo
9. Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double‐Blind, Placebo‐Controlled REGAIN, and Pooled EVOLVE‐1 and EVOLVE‐2 Studies
10. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder
11. Quality of life in children and adolescents with bipolar I depression treated with olanzapine/fluoxetine combination
12. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: Results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart 1型糖尿病患者连续使用胰岛素泵6天后的血糖控制情况:赖脯胰岛素与门冬胰岛素的双盲、开放标签、交叉试验
13. A Randomized Trial of Edivoxetine in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder
14. Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine
15. Pain Response Profile of Patients With Fibromyalgia Treated With Duloxetine
16. Effect of duloxetine in patients with fibromyalgia: tiredness subgroups
17. A 1-year Safety and Efficacy Study of Duloxetine in Patients With Fibromyalgia
18. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms
19. 5-HT1A receptors mediate (+)8-OH-DPAT-stimulation of extracellular signal-regulated kinase (MAP kinase) in vivo in rat hypothalamus: Time dependence and regional differences
20. Duloxetine for the Treatment of Fibromyalgia in Women: Pooled Results from Two Randomized, Placebo-Controlled Clinical Trials
21. An Open-Label 52-Week Clinical Extension Comparing Duloxetine with Routine Care in Patients with Diabetic Peripheral Neuropathic Pain
22. Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain: Evaluation of Functional Outcomes
23. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: Results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart 1型糖尿病患者连续使用胰岛素泵6天后的血糖控制情况:赖脯胰岛素与门冬胰岛素的双盲、开放标签、交叉试验
24. Duloxetine
25. Duloxetine in the long-term management of diabetic peripheral neuropathic pain: An open-label, 52-week extension of a randomized controlled clinical trial
26. Duloxetine versus Routine Care in the Long-Term Management of Diabetic Peripheral Neuropathic Pain
27. A Double-Blind, Randomized Multicenter Trial Comparing Duloxetine with Placebo in the Management of Diabetic Peripheral Neuropathic Pain
28. Is treatment-associated hypomania rare with duloxetine: Secondary analysis of controlled trials in non-bipolar depression
29. Short-Term Cocaine Treatment Causes Neuroadaptive Changes in Gαq and Gα11 Proteins in Rats Undergoing Withdrawal
30. Desensitization of 5-HT1AReceptors by 5-HT2AReceptors in Neuroendocrine Neurons in Vivo
31. Estrogen Reduces Serotonin-1A Receptor-Mediated Oxytocin Release and Gαi/o/z Proteins in the Hypothalamus of Ovariectomized Rats
32. A Region-Specific Increase in Gαq And Gα11 Proteins in Brains of Rats during Cocaine Withdrawal
33. Modulation of glutamate receptor expression by gonadal steroid hormones in the rat striatum
34. Evidence That 5-HT2AReceptors in the Hypothalamic Paraventricular Nucleus Mediate Neuroendocrine Responses to (−)DOI
35. Sexually dimorphic effects of morphine and MK-801: sex steroid-dependent and -independent mechanisms
36. A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia.
37. Estrogen Reduces Serotonin-1A Receptor-Mediated Oxytocin Release and Gαi/o/z Proteins in the Hypothalamus of Ovariectomized Rats.
38. Hepatic Effects of Duloxetine - III: Analysis of Hepatic Events Using External Data Sources
39. Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies
40. Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies
41. Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies
42. Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies
43. 5-HT1A receptors mediate (+)8-OH-DPAT-stimulation of extracellular signal-regulated kinase (MAP kinase) in vivo in rat hypothalamus: Time dependence and regional differences
44. Hepatic effects of duloxetine-I: non-clinical and clinical trial data.
45. Hepatic effects of duloxetine-II: spontaneous reports and epidemiology of hepatic events.
46. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder.
47. Desensitization of 5-HT1A receptors by 5-HT2A receptors in neuroendocrine neurons in vivo.
48. Estrogen reduces serotonin-1A receptor-mediated oxytocin release and Galpha(i/o/z) proteins in the hypothalamus of ovariectomized rats.
49. Modulation of glutamate receptor expression by gonadal steroid hormones in the rat striatum.
50. Evidence that 5-HT2A receptors in the hypothalamic paraventricular nucleus mediate neuroendocrine responses to (-)DOI.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.